Volume 6 Issue 2
Dec.  2022
Turn off MathJax
Article Contents
Article Navigation >  Blood&Genomics  > 2022  >  6(2): 103-113
Jikai He, Jiaqi Jia, Wenhao Qu, Lizhou Jia, Wei Zhao. The function and regulatory mechanism of B cells in tumor immunity[J]. Blood&Genomics, 2022, 6(2): 103-113. doi: 10.46701/BG.2022022022031
Citation: Jikai He, Jiaqi Jia, Wenhao Qu, Lizhou Jia, Wei Zhao. The function and regulatory mechanism of B cells in tumor immunity[J]. Blood&Genomics, 2022, 6(2): 103-113. doi: 10.46701/BG.2022022022031
shu

The function and regulatory mechanism of B cells in tumor immunity

doi: 10.46701/BG.2022022022031
  • 1.

    Research Center for Prevention and Treatment of Drug Resistant Microbial Infection, Youjiang Medical University for Nationalities, Baise, Guangxi 533000, China

  • 2.

    Department of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China

Funds:  Review Article
More Information
  • Corresponding author: Wei Zhao, Department of Pathology, Nanjing First Hospital, Nanjing Medical University, No. 68 Changle Road, Nanjing, Jiangsu 210006, China. E-mail: zhaowei_njmu@163.com
  • Received Date: 2022-11-04
  • Rev Recd Date: 2022-11-28
  • Accepted Date: 2022-11-29
    • Available Online: 2023-07-17
  • Publish Date: 2022-12-30
    Abstract
  • B cells are important components of the human immune system, and play a role in the process of specific immunity. In recent years, research on B cells and tumor immunity has made rapid progress. Studies have shown that different types of B cells play different roles in the tumor microenvironment (TME) through a variety of mechanisms. Tumor-infiltrating B cells (TIBs) in the TME play an anti-tumor role by secreting antibodies and presenting antigens, while regulatory B cells (Bregs) inhibit the immune response by secreting a variety of cytokines, thereby promoting tumor immune escape. This review introduces the roles and mechanisms of different subtypes of B cells in different types of tumors.

     

    • FullText(HTML)
  • loading
    • References(85)
  • [1]
    Lianyuan T, Dianrong X, Chunhui Y, et al. The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC)[J]. Cancer Biol Ther, 2018, 19(4): 296−305. doi: 10.1080/15384047.2017.1416932
    [2]
    Li Q, Teitz-Tennenbaum S, Donald EJ, et al. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy[J]. J Immunol, 2009, 183(5): 3195−3203. doi: 10.4049/jimmunol.0803773
    [3]
    Shen S, Xu Z, Qian X, et al. Autogeneic rna-electroporated CD40-ligand activated b-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo[J]. Exp Oncol, 2007, 29(2): 137–143.
    [4]
    Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function[J]. Immunity, 2015, 42(4): 607−612. doi: 10.1016/j.immuni.2015.04.005
    [5]
    Mahmoud SM, Lee AH, Paish EC, et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast[J]. Breast Cancer Res Treat, 2012, 132(2): 545−553. doi: 10.1007/s10549-011-1620-1
    [6]
    Qin Y, Peng F, Ai L, et al. Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis[J]. Cancer Cell Int, 2021, 21(1): 310. doi: 10.1186/s12935-021-02004-9
    [7]
    Schalper KA, Brown J, Carvajal-Hausdorf D, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer[J]. J Natl Cancer Inst, 2015, 107(3): dju435. doi: 10.1093/jnci/dju435
    [8]
    Fridman WH, Petitprez F, Meylan M, et al. B cells and cancer: to B or not to B?[J]. J Exp Med, 2021, 218(1): e20200851. doi: 10.1084/jem.20200851
    [9]
    Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression[J]. Cancer Res, 2019, 79(18): 4557−4566. doi: 10.1158/0008-5472.Can-18-3962
    [10]
    Xie Y, Xie F, Zhang L, et al. Targeted anti-tumor immunotherapy using tumor infiltrating cells[J]. Adv Sci (Weinh), 2021, 8(22): e2101672. doi: 10.1002/advs.202101672
    [11]
    Ager A, May MJ. Understanding high endothelial venules: lessons for cancer immunology[J]. Oncoimmunology, 2015, 4(6): e1008791. doi: 10.1080/2162402x.2015.1008791
    [12]
    Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances[J]. Nat Rev Cancer, 2018, 18(3): 148−167. doi: 10.1038/nrc.2017.121
    [13]
    Melo-Gonzalez F, Kammoun H, Evren E, et al. Antigen-presenting ILC3 regulate T cell-dependent IgA responses to colonic mucosal bacteria[J]. J Exp Med, 2019, 216(4): 728−742. doi: 10.1084/jem.20180871
    [14]
    Wang SS, Liu W, Ly D, et al. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer[J]. Cell Mol Immunol, 2019, 16(1): 6−18. doi: 10.1038/s41423-018-0027-x
    [15]
    Michaud D, Steward CR, Mirlekar B, et al. Regulatory B cells in cancer[J]. Immunol Rev, 2021, 299(1): 74−92. doi: 10.1111/imr.12939
    [16]
    Sautès-Fridman C, Verneau J, Sun CM, et al. Tertiary lymphoid structures and B cells: clinical impact and therapeutic modulation in cancer[J]. Semin Immunol, 2020, 48: 101406. doi: 10.1016/j.smim.2020.101406
    [17]
    Jia L, Wang T, Zhao Y, et al. Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas[J]. Oncoimmunology, 2021, 10(1): 1969767. doi: 10.1080/2162402x.2021.1969767
    [18]
    Chiaruttini G, Mele S, Opzoomer J, et al. B cells and the humoral response in melanoma: the overlooked players of the tumor microenvironment[J]. Oncoimmunology, 2017, 6(4): e1294296. doi: 10.1080/2162402x.2017.1294296
    [19]
    Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens[J]. Cancer Immunol Immunother, 2009, 58(10): 1535−1544. doi: 10.1007/s00262-009-0733-4
    [20]
    Guillem EB, Sampsel JW. Antitumor-associated antigens IgGs: dual positive and negative potential effects for cancer therapy[J]. Adv Exp Med Biol, 2006, 587: 341−374. doi: 10.1007/978-1-4020-5133-3_26
    [21]
    Oh JE, Iijima N, Song E, et al. Migrant memory B cells secrete luminal antibody in the vagina[J]. Nature, 2019, 571(7763): 122−126. doi: 10.1038/s41586-019-1285-1
    [22]
    Talebian Yazdi M, Loof NM, Franken KL, et al. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma[J]. Cancer Immunol Immunother, 2015, 64(9): 1109−1121. doi: 10.1007/s00262-015-1716-2
    [23]
    Kurtenkov O, Innos K, Sergejev B, et al. The Thomsen-Friedenreich antigen-specific antibody signatures in patients with breast cancer[J]. Biomed Res Int, 2018, 2018: 9579828. doi: 10.1155/2018/9579828
    [24]
    Avalos AM, Ploegh HL. Early BCR events and antigen capture, processing, and loading on MHC class Ⅱ on B cells[J]. Front Immunol, 2014, 5: 92. doi: 10.3389/fimmu.2014.00092
    [25]
    Phan TG, Grigorova I, Okada T, et al. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells[J]. Nat Immunol, 2007, 8(9): 992−1000. doi: 10.1038/ni1494
    [26]
    Mizoguchi A, Mizoguchi E, Takedatsu H, et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation[J]. Immunity, 2002, 16(2): 219−230. doi: 10.1016/s1074-7613(02)00274-1
    [27]
    Moore DK, Loxton AG. Regulatory B lymphocytes: development and modulation of the host immune response during disease[J]. Immunotherapy, 2019, 11(8): 691−704. doi: 10.2217/imt-2018-0185
    [28]
    Matsumoto M, Baba A, Yokota T, et al. Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation[J]. Immunity, 2014, 41(6): 1040−1051. doi: 10.1016/j.immuni.2014.10.016
    [29]
    Chen Z, Zhu Y, Du R, et al. Role of regulatory B cells in the progression of cervical cancer[J]. Mediators Inflamm, 2019, 2019: 6519427. doi: 10.1155/2019/6519427
    [30]
    Wang X, Li J, Lu C, et al. IL-10-producing B cells in differentiated thyroid cancer suppress the effector function of T cells but improve their survival upon activation[J]. Exp Cell Res, 2019, 376(2): 192−197. doi: 10.1016/j.yexcr.2019.01.021
    [31]
    Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases[J]. Nature, 2014, 507(7492): 366−370. doi: 10.1038/nature12979
    [32]
    Sakkas LI, Mavropoulos A, Perricone C, et al. IL-35: a new immunomodulator in autoimmune rheumatic diseases[J]. Immunol Res, 2018, 66(3): 305−312. doi: 10.1007/s12026-018-8998-3
    [33]
    Tavakolpour S, Kheiry F, Mirsafaei HS, et al. The possible role of interleukin-35 and its therapeutic potential in pemphigus[J]. Int Immunopharmacol, 2017, 42: 11−17. doi: 10.1016/j.intimp.2016.11.005
    [34]
    Egwuagu CE, Yu CR, Sun L, et al. Interleukin 35: critical regulator of immunity and lymphocyte-mediated diseases[J]. Cytokine Growth Factor Rev, 2015, 26(5): 587−593. doi: 10.1016/j.cytogfr.2015.07.013
    [35]
    Zhu Z, Zhang Y, Ye J, et al. IL-35 promoted STAT3 phosphorylation and IL-10 production in B cells, but its production was reduced in patients with coronary artery diseases[J]. Hum Immunol, 2018, 79(12): 869−875. doi: 10.1016/j.humimm.2018.10.009
    [36]
    Kao JY, Gong Y, Chen CM, et al. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine[J]. J Immunol, 2003, 170(7): 3806−3811. doi: 10.4049/jimmunol.170.7.3806
    [37]
    Kessel A, Haj T, Peri R, et al. Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells[J]. Autoimmun Rev, 2012, 11(9): 670−677. doi: 10.1016/j.autrev.2011.11.018
    [38]
    Cui C, Wang J, Fagerberg E, et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses[J]. Cell, 2021, 184(25): 6101−6118.e13. doi: 10.1016/j.cell.2021.11.007
    [39]
    Zhu W, Germain C, Liu Z, et al. A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality[J]. Oncoimmunology, 2015, 4(12): e1051922. doi: 10.1080/2162402x.2015.1051922
    [40]
    Eerola AK, Soini Y, Pääkkö P. Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma[J]. Lung cancer, 1999, 26(2): 73−83. doi: 10.1016/s0169-5002(99)00072-0
    [41]
    Liu J, Wang H, Yu Q, et al. RETRACTED: aberrant frequency of IL-10-producing B cells and its association with Treg and MDSC cells in Non Small Cell Lung Carcinoma patients[J]. Hum Immunol, 2016, 77(1): 84−89. doi: 10.1016/j.humimm.2015.10.015
    [42]
    Garaud S, Buisseret L, Solinas C, et al. Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer[J]. JCI insight, 2019, 5(18): e129641. doi: 10.1172/jci.insight.129641
    [43]
    Keren L, Bosse M, Marquez D, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging[J]. Cell, 2018, 174(6): 1373−1387.e19. doi: 10.1016/j.cell.2018.08.039
    [44]
    Seow DYB, Yeong JPS, Lim JX, et al. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers[J]. Breast Cancer Res Treat, 2020, 180(2): 369−377. doi: 10.1007/s10549-020-05548-y
    [45]
    Guan H, Lan Y, Wan Y, et al. PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer[J]. Oncoimmunology, 2016, 5(2): e1075112. doi: 10.1080/2162402x.2015.1075112
    [46]
    Delvecchio FR, Goulart MR, Fincham REA, et al. B cells in pancreatic cancer stroma[J]. World J Gastroenterol, 2022, 28(11): 1088−1101. doi: 10.3748/wjg.v28.i11.1088
    [47]
    Gunderson AJ, Kaneda MM, Tsujikawa T, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer[J]. Cancer Discov, 2016, 6(3): 270−285. doi: 10.1158/2159-8290.Cd-15-0827
    [48]
    Lee KE, Spata M, Bayne LJ, et al. Hif1a deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia[J]. Cancer Discov, 2016, 6(3): 256−269. doi: 10.1158/2159-8290.Cd-15-0822
    [49]
    Li S, Mirlekar B, Johnson BM, et al. STING-induced regulatory B cells compromise NK function in cancer immunity[J]. Nature, 2022, 610(7931): 373−380. doi: 10.1038/s41586-022-05254-3
    [50]
    Castino GF, Cortese N, Capretti G, et al. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma[J]. Oncoimmunology, 2016, 5(4): e1085147. doi: 10.1080/2162402x.2015.1085147
    [51]
    Meshcheryakova A, Tamandl D, Bajna E, et al. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer[J]. PLoS One, 2014, 9(6): e99008. doi: 10.1371/journal.pone.0099008
    [52]
    Shen T, Liu JL, Wang CY, et al. Targeting Erbin in B cells for therapy of lung metastasis of colorectal cancer[J]. Signal Transduct Target Ther, 2021, 6(1): 115. doi: 10.1038/s41392-021-00501-x
    [53]
    Berntsson J, Nodin B, Eberhard J, et al. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer[J]. Int J Cancer, 2016, 139(5): 1129−1139. doi: 10.1002/ijc.30138
    [54]
    Edin S, Kaprio T, Hagström J, et al. The prognostic importance of CD20+ B lymphocytes in colorectal cancer and the relation to other immune cell subsets[J]. Sci Rep, 2019, 9(1): 19997. doi: 10.1038/s41598-019-56441-8
    [55]
    He W, Wang B, He J, et al. SSR4 as a prognostic biomarker and related with immune infiltration cells in colon adenocarcinoma[J]. Expert Rev Mol Diagn, 2022, 22(2): 223−231. doi: 10.1080/14737159.2022.2019015
    [56]
    Henriksen JR, Nederby L, Donskov F, et al. Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy[J]. J Ovarian Res, 2020, 13(1): 59. doi: 10.1186/s13048-020-00661-4
    [57]
    Biswas S, Mandal G, Payne KK, et al. IgA transcytosis and antigen recognition govern ovarian cancer immunity[J]. Nature, 2021, 591(7850): 464−470. doi: 10.1038/s41586-020-03144-0
    [58]
    Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic t-cell responses, and superior prognosis in ovarian cancer[J]. Clin Cancer Res, 2016, 22(12): 3005−3015. doi: 10.1158/1078-0432.Ccr-15-2762
    [59]
    Lichtman A. The ABCs of ovarian cancer immunology: IgA, B cells, and CTLs[J]. Sci Immunol, 2021, 6(57): eabh3184. doi: 10.1126/sciimmunol.abh3184
    [60]
    Lundgren S, Berntsson J, Nodin B, et al. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer[J]. J Ovarian Res, 2016, 9: 21. doi: 10.1186/s13048-016-0232-0
    [61]
    Yang C, Lee H, Jove V, et al. Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer[J]. PLoS One, 2013, 8(1): e54029. doi: 10.1371/journal.pone.0054029
    [62]
    Ni Z, Xing D, Zhang T, et al. Tumor-infiltrating B cell is associated with the control of progression of gastric cancer[J]. Immunol Res, 2021, 69(1): 43−52. doi: 10.1007/s12026-020-09167-z
    [63]
    Wang WW, Yuan XL, Chen H, et al. CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer[J]. Oncotarget, 2015, 6(32): 33486−33499. doi: 10.18632/oncotarget.5588
    [64]
    Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma[J]. Gut, 2017, 66(2): 342−351. doi: 10.1136/gutjnl-2015-310814
    [65]
    Brunner SM, Itzel T, Rubner C, et al. Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival[J]. Oncotarget, 2017, 8(41): 71002−71011. doi: 10.18632/oncotarget.20238
    [66]
    Shao Y, Lo CM, Ling CC, et al. Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway[J]. Cancer Lett, 2014, 355(2): 264−272. doi: 10.1016/j.canlet.2014.09.026
    [67]
    Xue H, Lin F, Tan H, et al. Overrepresentation of IL-10-expressing B cells suppresses cytotoxic CD4+ T cell activity in HBV-induced hepatocellular carcinoma[J]. PLoS One, 2016, 11(5): e0154815. doi: 10.1371/journal.pone.0154815
    [68]
    Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma[J]. Cancer Res, 2012, 72(5): 1070−1080. doi: 10.1158/0008-5472.Can-11-3218
    [69]
    Garg K, Maurer M, Griss J, et al. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome[J]. Hum Pathol, 2016, 54: 157−164. doi: 10.1016/j.humpath.2016.03.022
    [70]
    Gilbert AE, Karagiannis P, Dodev T, et al. Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies[J]. PLoS One, 2011, 6(4): e19330. doi: 10.1371/journal.pone.0019330
    [71]
    Bosisio FM, Wilmott JS, Volders N, et al. Plasma cells in primary melanoma. Prognostic significance and possible role of IgA[J]. Mod Pathol, 2016, 29(4): 347−358. doi: 10.1038/modpathol.2016.28
    [72]
    Somasundaram R, Zhang G, Fukunaga-Kalabis M, et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance[J]. Nat Commun, 2017, 8(1): 607. doi: 10.1038/s41467-017-00452-4
    [73]
    Kobayashi T, Oishi K, Okamura A, et al. Regulatory B1a cells suppress melanoma tumor immunity via IL-10 production and inhibiting T helper type 1 cytokine production in tumor-infiltrating CD8+ T cells[J]. J Invest Dermatol, 2019, 139(7): 1535−1544.e1. doi: 10.1016/j.jid.2019.02.016
    [74]
    Svensson MC, Warfvinge CF, Fristedt R, et al. The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma[J]. Oncotarget, 2017, 8(42): 72108−72126. doi: 10.18632/oncotarget.19437
    [75]
    Wang Z, Cheng Z, Lu S, et al. Characterization of the intra-tumoral B cell immunoglobulin repertoire is of prognostic value for esophageal squamous cell carcinoma[J]. Front Immunol, 2022, 13: 896627. doi: 10.3389/fimmu.2022.896627
    [76]
    Lu L, Weng C, Mao H, et al. IL-17A promotes migration and tumor killing capability of B cells in esophageal squamous cell carcinoma[J]. Oncotarget, 2016, 7(16): 21853−21864. doi: 10.18632/oncotarget.7869
    [77]
    Kam NW, Wu KC, Dai W, et al. Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma[J]. Angiogenesis, 2022, 25(2): 181−203. doi: 10.1007/s10456-021-09819-0
    [78]
    Wieland A, Patel MR, Cardenas MA, et al. Defining HPV-specific B cell responses in patients with head and neck cancer[J]. Nature, 2021, 597(7875): 274−278. doi: 10.1038/s41586-020-2931-3
    [79]
    Pretscher D, Distel LV, Grabenbauer GG, et al. Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma[J]. BMC Cancer, 2009, 9: 292. doi: 10.1186/1471-2407-9-292
    [80]
    DeFalco J, Harbell M, Manning-Bog A, et al. Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens[J]. Clin Immunol, 2018, 187: 37−45. doi: 10.1016/j.clim.2017.10.002
    [81]
    Lechner A, Schlößer HA, Thelen M, et al. Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma[J]. Oncoimmunology, 2019, 8(3): 1535293. doi: 10.1080/2162402x.2018.1535293
    [82]
    Jeske SS, Brand M, Ziebart A, et al. Adenosine-producing regulatory B cells in head and neck cancer[J]. Cancer Immunol Immunother, 2020, 69(7): 1205−1216. doi: 10.1007/s00262-020-02535-6
    [83]
    Meylan M, Petitprez F, Becht E, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer[J]. Immunity, 2022, 55(3): 527−541.e5. doi: 10.1016/j.immuni.2022.02.001
    [84]
    Lin Z, Liu L, Xia Y, et al. Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors[J]. Oncoimmunology, 2018, 7(10): e1477461. doi: 10.1080/2162402x.2018.1477461
    [85]
    Yao C, Yu H, Zhou G, et al. Tumor-infiltrating plasma cells are the promising prognosis marker for esophageal squamous cell carcinoma[J]. Esophagus, 2021, 18(3): 574−84. doi: 10.1007/s10388-021-00828-y
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (224) PDF downloads(14) Cited by()
    Proportional views
    Related

    Copyright © Blood and Genomics苏公网安备 32028102000501号苏ICP备14047883号-6

    Address：Rooms 1318-19, Hollywood Plaza, 610 Nathan Road, Mongkok, Kowloon, HongKong

    E-mail：editorial_office@apjbg.com

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return